CDC Vaccine Panel Endorses Merck’s RSV Shot for Infants: A Potential Game-Changer in Pediatric Health and Pharma Investments
Merck’s New RSV Shot: A Game-Changer for Infant Health and What It Means for Investors The recent unanimous recommendation by the revamped Advisory Committee on Immunization Practices (ACIP) to include Merck’s Enflonsia in the government’s childhood immunization schedule marks a pivotal moment—not just for public health, but for savvy investors eyeing the vaccine sector. This…